Maball 500mg Injection

Non-Hodgkin lymphoma (NHL)
Blood cancer (Chronic lymphocytic leukemia)
Rheumatoid arthritis
Granulomatosis with polyangiitis
Microscopic polyangiitis

Maball 500mg Injection may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.
Headache
Cough Fever and Chills Hair loss
Decrease in WBC, RBC, and Platelets
Skin rash Insomnia
Sore throat

Maball 500mg Injection is given under the supervision of a professional healthcare provider. Make sure to have a word with your healthcare provider regarding your medical condition and medical history. Also, give access to the list of medicines you already take. Seek immediate medical help in case of overdose.

Maball 500mg Injection links to the CD20 antigen on normal and malignant B-cells. Therefore, the essential immune system of the body is initiated to attack and then kill the marked B-cells. Stem cells in the bone marrow grow into various cell types. They do not have the CD20 antigen. After the treatment, the CD20 antigen allows the multiplication of healthy B-cells.

​In case you miss a dose, make sure to consult your healthcare provider to get proper guidance. Do not double the dose for compensation.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Feder, O., Amsterdam, D., Ershed, M., et al. (2025). Long‑term efficacy of rituximab in steroid‑dependent and frequent relapsing adult nephrotic syndrome. BMC Nephrology, 26, 126.

Kalenik, V. A., Belada, D., Oliveira, A. C., et al. (2024). Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera® in low-tumor-burden follicular lymphoma: The FLINTER study. Blood, 144 (Supplement 1), 6276

Kimby, E. K., Schär, S., Pirosa, M. C., et al. (2025). Six‑month rituximab‑lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10‑year update. Blood Advances.

Maharaj, N., Uppada, D. R., Reddy, N., et al. (2024). Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: A randomized, double‑blind, phase 3 study. Arthritis Research & Therapy, 26, 225.

Zheng, X., Di, J., Chen, X., Li, F., Liu, Y., Cao, J., Ning, X., Wei, L., & Zheng, G. (2025). Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren’s syndrome. Frontiers in Immunology, 16, 1561214.